Artículo Especial

De la Alergia Clínica a la Alergia Molecular: Concisa historia de cien años

Wenceslao Sánchez de la Vega, Ernesto Sánchez de la Vega


Texto completo solo disponible en PDF
Este artículo no contiene resumen

Este artículo no contiene abstract

Los autores declaran no poseer conflictos de intereses.

Fuente de información Asociación Argentina de Alergia e Inmunología Clínica. Para solicitudes de reimpresión a Archivos de Alergia e Inmunología Clínica hacer click aquí.

Recibido | Aceptado | Publicado 2007-10-01

  1. Ring J. History of anaphylaxis. Allergy Clin Immunol Intern 2003;15:144-48.

  2. Egypt and the Ebers papyrus. In: Ancestors of Alergy. Simons F (ed). New York. Global Medical Communications, 1944, pp. 38-44.

  3. Ibid.

  4. Panzani RC. Seneca and his asthma: the illnesses, life and death of a Roman stoic philosopher. J of Asthma 1988;35:163-74.

  5. Roger Ellul-Micallef. History of asthma. In: Asthma, J P Barnes (ed). Lippincott- Raven Publishers, Philadelphia, 1997.

  6. Salter Henry. On the treatment of asthma by belladonna. Lancet I 1869; pp. 152-153.

  7. Bostock J. Case of a periodical affection of the eyes end the chest. Medico-Chirurgical Transactions. 1819;10:161-2.

  8. Blackey Charles. Experimental Researches on the Causes and Nature of Catarrhus Aestivus (Hay-Fever or Hay-Asthma). In: Marc Jackson. Allergy: The History of a Modern Malady. Reaction Books LTD (ed). London, 2006, p. 60.

  9. Ibid.

  10. Portier et Richet. De l’action anaphylactic de certains venins. Comp Rend Soc Biol 1902;54:170-72.

  11. Clemens von Pirquet. “Allergie”. Münchr Med Wochensrchr 1906;30:1457-8.

  12. Doerr R. El término técnico. En: La Anafilaxia. Revista de Occidente (ed). Madrid, 1954, p. 2-5.

  13. Rojido GM. Cien años de anafilaxia. Alergol Immunol Clin 2001;16:344-348.

  14. Von Pirquet C, Shick B. Zur theorie der incubationszeit. Wiener Klinische Wochenschrift 1903;16:1244.

  15. Arthus M. Injections repetées de serum de cheval chez le lapin. Comp Rendus Soc Biol 1903;55;817-25.

  16. Ramirez M. Horse asthma following blood tranfusion; report of a case. JAMA 1919: 73: 984-85.

  17. Praunitz y Küstner. Estudios sobre supersensibilidad. En: Gell y Coombs. Clínica Inmunológica. Salvat (ed) Bs. As. 1965, pp. 750-757.

  18. Ovary Zoltan. Immediate reactions in the skin of experimental animals provoked by antigen-antibody ìnteraction. Prog Allerg 1958;5:459-463.

  19. Coca AF, Cooke RA. On the classification of the phenomena of hypersensitiveness. J Immunol 1923:8;163-82.

  20. Hansen K. Tratado de Alergia. Labor (edit). Bs.As. 1946.

  21. Coca A. Study of atopic reagins. 1925;10:445-464.

  22. Cooke RA. Allergy in theory and practice.WB Saunders edit. Philadelphia, 1947.

  23. Coca AF. The pulse test. Lyle Stuart (ed) New York 1958. p. 7.

  24. Sherman WB Atopy. In Sherman WB ed. Hypersensitivity, mechanismand management. Philadelphia, 1968. p. 52-53.

  25. Oehling A. Alergología e Inmunología Clínica. Interamericana (ed).Madrid, 1965. p. 5.

  26. Tiselius A, Kabat A E. An electrophoretoc study of immune sera and purified antibody preparation. J Exp Med 1939;69:119-131.

  27. Heremans JF, Vaerman JP. β2A globulin as a possible carrier of allergic reaginic activity. Nature (London) 1962:193:1091-95.

  28. Binaghi R, Benacerraf B. The production of anaphylactic antibody in the rat. J Immunol 1964;92:920-925.

  29. Binaghi R, et al. Les anticorps anaphylactics des mamiferes. Bull Instit Pasteur 1973;71:249-279.

  30. Ishizaka K, Ishizaka T, Hornbrook MM. Physicochemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J. Immunol. 1966 97:75-85.

  31. Ishizaka K, Ishizaka T, and Hornbrook MM. Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity with γE globulin antibody. J. Immunol.1996 97:840-853. 29.

  32. Ishizaka K, Izhizaka T. Identification of γE antibodies as a carrier of reaginic activity. J Immunol 1967;99:1167-1198.

  33. Johansson SGO, Bennich H. Immunologigal studies of an atypical (myeloma) immunoglobulin. Immunology 1967;13:361-381.

  34. Johansson SGO, Bennich H, Widt L. A new class of Immunoglobulin en human serum. Immunology 1967;14:265-272.

  35. Une nouvelle clase d´inmunoglobuline humaine, l´inmunoglobuline E. OMS Bull 1968:38;151-152.

  36. Ishizaka K, Ishizaka T, Menzel AEO. Physicochemical propiertes of reaginic antibody. J Immunol 1967;99:610-618.

  37. Ishizaka K, Ishizaka T. Human reaginic antibodies and Immunoglobulin E. J Allergy 1968;42:330-363.

  38. Van T, et al. The crystal structure of IgE Fc reveals an asymetrical bent conformation.Nature Immunol 2002;3:681-686.

  39. De Weck AL, Sanz ML. Flow Cytometric Cellular Allergen Stimulation Test (FAST/ Flow CAST). Technical and clinical evaluation of a new diagnostic test in allergy and pseudoallergy. ACI International 2002;14: 204-215.

  40. Johansson SGO. Raised levels of a new inmunoglobulin class (IgND) in asthma. Lancet 1967;2:951-953.

  41. Zettreström O, Johansson SGO. IgE concentrations measured by PRIST in serum of healthy adults and in patients with respiratory allergy. Allergy 1981;36:537-547.

  42. Yazdanbakhsh M, et al. Th2 responses without atopy: immunoregulation in chronic helminth infections and reduced allergic desease. Trends in Immunol 2001;22:372-377.

  43. Stanworth DR, et al. Specific inhibition of the Prausnitz-Küstner reaction by an atypical human myeloma protein. The Lancet 1967;2:330-332.

  44. Binaghi R. Función biológica de la IgE. Arch Arg de Alergia e Immunol Clin 1999;30:8-13.

  45. Kohlson G. A place for histamine in normal physiology. Lancet 1960;1:67-72.

  46. Novak N, et al. IgE receptors. Curr Opin in Immunol 2001;13:721-726.

  47. Kikutami H, Kishimoto T. The B lymphocyte receptor for IgE. Allergy Clin Int News 1989;1:116-119.

  48. Metzger H, Kinet JP. Model of high affinity receptor for IgE. Allergy Clin Int News 1989;1:119.

  49. Novak N, et al. FcεRI engagement of Langerhans cell-like dendritic cells and inflammation dendritic epidermal cell-like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro. J Allergy Clin Immnunol 2004;113:949-957.

  50. Tada T, Ishizaka K. Distribution of γE-forming cells in lymphoid tissues of human and monkey. J Immunol 1970;104:377-387.

  51. Tada T, Taniguchi M, Okumura K. Regulation of homocitotropic antibody formation in the rat.II. Effect of X-irradiation. J Immunol 1971:106;1012-18.

  52. Mosman, et al. Two types of murine helper T cell clone. Definition according to profiles of lymphoquine activities and secreted proteins. J Immunol 1986;136:2348-2357.

  53. Sutton B, Gould H. The human IgE network. Nature 1993;366:421-430.

  54. Geha R. Molecular mechanisms of Immunoglobulin E regulation. Intern Arch of Allergy and Immunol 1998;115:257-259.

  55. Meyers D. Genetics of asthma. Allergy Clin Immunol Int 2001;13:74-75.

  56. Halloway JW, Koppelman GH. Identifyng novel genes contributing to asthma pathogenesis. Curr Opin Allergy Clin Immunol 2007;7:69-74.

  57. Papi A. Epithelial ICAM-1 regulation and its rol in allergy. Clin Exp Allergy 1997:27:721-24.

  58. O´Byrne PM. Cytokines or their antagonist for the treatment of asthma. Chest 2006;130;244-250.

  59. Wechsler ME, et al. β-adrenergic receptor polymorphism and response to salmeterol. Am J Resp Cret Care Med 2005;173:519-526.

  60. Stadler BM, Furukawa K. Immunoglobulin E regulation beyond the cytokine network.Allergy Clin Immunol News 1993;5/6:160-162.

  61. Kirshembaun AS, et al. Efect of IL-3 and stem cell factor on the appearance of human basohil and mast cell from CD34 pluripotent progenitor cells. J Immunol 1992;148:772-777.

  62. Church MK, Levi-Schaffer. The human mast cell. J Allergy Clin Immunol 1997;99:155-160.

  63. Black J (ed) The role of Mast Cells in the Pathophysiology of Asthma. N Engl J Med 2002;346:1742-1743.

  64. Kitamura Y, et al. The usefulness of mast cell deficient animals for allergy research. Allergy Clin Inmunol News 1991;3:150-151.

  65. Riley JF, West GB. The presence of histamine in tissue mast cells. J Physiol 1953;120:528-540.

  66. Irani AA, et al. Two tipes of human mast cells that have subsets with distint neutral protease compositions. Proc Natl Acad Sci USA 1986;83:4464-8.

  67. Irani A M., Schwart L. Heterogeneidad de las células cebadas humanas. Allergy Proceed. 1995;3:39-44 (ed. española).

  68. Marone G. The concept of basophil and mast cell releasability. Allergy Clin Immunol News 1993;5:31-32.

  69. Tkaczyk, et al. FcyRI and other Fc receptors on human mast cell. Allergy Clin Immunol Int 2002;14:109-116.

  70. Schwartz L. Tryptase: A clinical indicator of mast cell-dependent events. Allergy Proc 1994;15:119-123.

  71. Lin RY, Schwartz LB, Curry A, Pesola GR, Knight RJ, Lee HS, et al. Histamine and tryptase levels in patients with acute allergic reactions: An emergen department based study. J Allergy Clin Immunol 2000; 106: 65-71.

  72. Kobayasi H, et al. Human mast cells and basophils as sources of cytokines. Clin Exp Immunol 2000;30:1205-1212.

  73. Galli SJ, Wershil BK. The two faces of mast cells. Nature 1996;381:21- 22.

  74. Feger F, et al. The role of mast cells in host defense and their subversión by bacterial pathogens. Trends in Immunol 2002;23:151-158.

  75. Wooley DE. The mast cell in inflammatory arthritis. N Engl J Med 2003;348:1709-1711.

  76. Fukuishi N, et al. Sounding the alarm in infection. Allergy Clin Immunol Int. 2004;16:70-74.

  77. Falcone FH, et al. The 21st century renaissance of the basophil? Current insights into its role in allergic responses and innate immunity. Experimental Dermatology 2006;15;855-864.

  78. Drunen CM, Fokkens WJ. Basophils and mast cells at the center of the immunological response. Allergy 2006;61:273-275.

  79. Prin L, et al. Heterogeneyty of human peripheral blood eosinophils; variability in cell density and citotoxic ability in relation to the level and the origin of hipereosinophilia. Int Arch Appl Immunol 1983;72:336-346.

  80. Griffiths-Johnson DA, et al. The chemokine, eotaxin, activates guineapig eosinophils in vitro and causes their accumulation into the lung in vivo. Biochem Biophys Res Commun 1983;197:881-887.

  81. Cooke EB, et al. Epithelial cells are a major cellular source of the chemokine eotaxin in the guinea pig lung. Allergy Asthma Proc 1998;19:15-22.

  82. Cyr MM, Denburg JA. Systemic aspect of allergic desease: the role of the bone marrow. Curr Opin in Immunol 2001;13:727-732.

  83. Conroy DM, Williams TJ. Eotaxin and the attraction of eosinophils to asmathic lung. Resp Research 2001;2:150-156.

  84. Monteseirin J, et al. ¿Es el neutrófilo una célula reguladora del eosinófilo en los procesos alérgicos mediados por la IgE? Allergol Inmunol Clin 2004;19:7-12.

  85. Jenkins HA, et al. Histopatology of sever childhood asthma: a case series. Chest 2003;124:32-41.

  86. H. Sherwood Lawrence. Some biological and immunological properties of transfer factor. Ciba foundation on cellular aspects of immunity. JA Churchill, Ltd. London 1960, pp 243-279.

  87. Stoitzner P, Pfaller K, Stössel H, Romani N. A close-up view of migrating Langerhans cells in the skin. J Invest Dermatol 2002, 118:117-25.

  88. Gell y Coombs. Clínica Inmunológica. Salvat edit. Bs. As. 1965.

  89. Dolovich J, et al. Late cutaneous allergic responses in isolated IgE-dependent reactions. J Allergy Clin Immunol 1973;52:38-46.

  90. Hansen K. Tratado de Alergia. Labor edit. Bs. As.1946, p. 244.

  91. Voorhorst R, Spieksma FTM, et al. The house dust mite (Dermatophagoides pteronyssinus) and the allergens it produces: identity with the house dust allergens. J Allergy 1967;39:325-339.

  92. Mathov E.

  93. Aberer W, et al. EAACI group on drug hipersensitivity. Allergy 2003;58:854-63.

  94. Dale HH, Laidlaw PP. Further observations on the action of β-imidazolylethylamine. J of Phisiology 1911;41:182-95.

  95. Lewis R. The blood vessels of the human skin and their responses. Shaw and Sons edit. London 1927.

  96. Best CG, Dale HH, Dudley HW, Thorpe MV. The nature of the vasodilator constituents of certain tissue extracts. J Physiol (Lond) 1927;62:397-417.

  97. Feldberg W. The action of histamine on de blood vessels of the rabbit. J Physiol (Lond) 1927;63:211-221.

  98. Ash ASF, Schild HO. Receptors mediating some actions of histamine. Br J Pharmacol 1966:27:427-439.

  99. Black JW, et al. Definitions and antagonism of histamine H2-receptors. Nature 1972;236:385-390.

  100. Arrang J M. et al. Auto-inhibition of brain histamine release mediate by a novel class (H3) of histamine receptor. Nature 1983:302:832-837.

  101. Nguyen T, Schapiro DA, George SR, et al. Discovery of a novel member of the histamine receptor family. Mol Pharmacol 2001;59:427-433.

  102. Dunford PJ, et al. Histamine H-4 receptor antagonist are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007;119:176-183.

  103. Church MK. Histamine receptors, inverse agonism, and allergy. Allergy Clin Immunol Int 2004;16:112-116.

  104. Kellaway C, Trethewile ER. The liberation of a slow smooth muscle stimulating substance in anaphylaxis. Quat J Exp Physiol 1940;30:121-128.

  105. Samuelsson B. Leucotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-573.

  106. Ogawa Y and Calhuen WJ. The role of leukotrienes in airway inflammation J Allergy Clin Immunol 2006,118:789-798.

  107. Hamberg M, Svenssin J and Samuelsson B. Tromboxanes: a new group of biologically active compound derived from prostagladins endoperoxidases. Pro Natl Acad Sci USA 1975;72:1994:2998.

  108. Schwartz L. Tryptase: A clinical indicator of mast cell-dependent events. Allergy Proc 1994;15:119-123.

  109. Noon L, Freedman N. Prophylactic inoculation against hay fever. Lancet 1911;2:1572-1573.

  110. Thomas WR, et al. Recombinant allergens for immunotherapy. Allergy Clin Immunol Int 2000;12:222-225.

  111. Krieg AM. The role of CpG motifs in innate immunity. Current opinion in Immunol 2000;12:35-43.

  112. Bieber T. Allergen-specific sublingual immunotherapy: less mystic, more scientific. Allergy 2006;61:149-150.

  113. Letherman BD, et al. Sublingual immunotherapy; past, present, paradigm for the future? A review of the literature. Otorinolaring Head and Neck Surgery 2007;3 supl:S1-S20.

  114. Akdis M, et al. Mechanims of allergen immunotherapy. Allergy Clin Immunol Int 2004;16:65-69.

  115. Akdis M, et al. T Regulatory cells in Allergy; Novel concepts in the pathogenesis, prevention and treatment of allergy deseases. J Allergy Clin Immunol 2005;116:961.

  116. Zhang K, et al. Chimeric Human-Allergen Fusion proteins in the prevention of Asthma. Immunol Allergy Clin of North America 2007;27:93-103.

  117. Matsubara S, et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airways hyperresponsiveness. Am J Respir Crit Care Med 2006;173:56-73.

  118. Milstein C, Köhker GK. Continous cultures of fused cells producing antibody of predefined specificity. Nature 1975:256;495-497.

  119. Busse W, et al. Omalizumab, anti-IgE recombinant monoclonal anti body, for the treatment of severe asthama. J. Allergy Clin Immunol 2001;108:184-190.

  120. Lanier BQ, Chang TW. Will anti-IgE therapy compromise normal immune functions? Allergy Clin Immunol Intern 2004;16:237-240.

  121. Birnbaum J, Vervloet D. Hymenoptera sting allergy. News in diagnosis and treatment. Allergy Clin Immunol Intern 2003;15:160-167.

  122. Freeman TM. Hypersensitivity to hymenoptera stings. N Engl J Med 2004;351:1978-1984.

  123. Hoffman D, et al. Allergen Nomenclature. Bull WHO 1994;72:786-806

  124. Chapman ND et al. Nomenclature and structural biology of allergen. J Allergy Clin Immunol 2007;119:414-420.

  125. Pisani S, et al. Sensibilización de cobayos a pólenes por inyección de extracto de naranja. Alergia (Buenos Aires) 1951;5:25-28.

  126. Pisani S, et al. Coincidencia antigénica entre alimentos y pólenes. La Semana Médica 1958;113:669-680.

  127. Vieths S, et al. Currente understanding of cross reactivity of food allergens and pollen. Ann N Y Acad Sci 2002;964:47-68.

  128. Egger M, et al. Pollen-fruits syndromes associated with weed pollinosis: an up date from the molecular point of view. Allergy 2006;61:461-466.

  129. Bovet D. Introduction to antihistamine agents and Antergan derivatives. Ann N Y Acad Sci 1950;50:1089-1126.

  130. Hench PS, et al. The Effect of a Hormone of the Adrenal Cortex (17- hydroxy- 11- dehydrocorticosterone: Compound E) and of Pituitary Adrenocorticotropic hormone on rheumatoid arthritis: Preliminary report. proc. Staff Meet. Mayo Clinic 1949;24:181-197.

  131. Cardone AL, Barousse AM. En defensa de la aminofilina. Medicina (Buenos Aires) 1999;59;107-108.

  132. Goodman, Gilman. Las bases farmacológicas de la terapéutica. Mc Graw-Hill Interamericana Edit. México 1996.

  133. Simons FE. Epinephrine absorption in adults: Intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001;108: 871-973.

  134. Sears MR, et el. Regular inhaled beta-agonist treatment in bronquial asthma, 1990;336:1391-1396.

  135. Wechsler ME. B2 Adrenergic receptor polymorfism and response to salmeterol. Am J Respir Crit Care Med 2005;173:519-526.

  136. Proppius H, Salorrine Y. Comparative trial of a new anticholinergic brochodilator, Sch 1000, and salbutamol in chronic bronchitis. Br Med J 1973:4:124-136.

  137. Kazanawa H. Anticholinergic agents in asthma: cronic bronchodilator therapy, relief of acute severe asthma, reduction of chronic viral inflammation and prevention of a airway remodeling Curr Opin Pulm Med 2006;2:60-67.

  138. Marx JL. The leukotrienes in allergy and inflammation. Science 1982;215:1380-1383.

  139. Drazen JM, Israel E, O´Byrne PM. Treatment of asthma with drugs modifying the leucotriene pathway. N Engl J Med 1999;340:197-206.

  140. A revised nomenclature for allergy: An EAACI position statement from EAACI nomenclature task force. Allergy 2001;56: 813-824.

  141. A revised nomenclature for allergy for global use. Report of the nomenclature review committee of the World Allergy Organization. Allergy Clin Immunol Int 2005;17:4-8.

  142. Johansson SGO. The revised allergy nomenclature. Allergy Clin Immunol Int 2005;17:128-130.

  143. Sheldon Cohen. Pionners and milestones. J Allergy Clin Immunol 2002;109:722-724.


Wenceslao Sánchez de la Vega
Vicepresidente de Fundaler.
Ernesto Sánchez de la Vega
Servicio de Alergia e Inmunología del Hospital Fernández.

Autor correspondencia

Wenceslao Sánchez de la Vega
Vicepresidente de Fundaler.

Correo electrónico: olwen@fibertel.com.ar

Para descargar el PDF del artículo
De la Alergia Clínica a la Alergia Molecular: Concisa historia de cien años

Haga click aquí

Para descargar el PDF de la revista completa
Archivos de Alergia e Inmunología Clínica , Volumen Año 2007 Num 3

Haga click aquí


Esta revista es una publicación de

Asociación Argentina de Alergia e Inmunología Clínica

Ir al sitio de la Sociedad

Este articulo pertenece a la revista

Archivos de Alergia e Inmunología Clínica

Ir al sitio de la revista

Archivos de Alergia e Inmunología Clínica
Número 3 | Volumen 38 | Año 2007

De la Alergia Clínica a la Alergia Molecular: Concisa historia de cien años

Wenceslao Sánchez de la Vega, Ernesto Sánchez de la Vega

Archivos de Alergia e Inmunología Clínica

Asociación Argentina de Alergia e Inmunología Clínica

Fecha de publicación

Registro de propiedad intelectual
© Asociación Argentina de Alergia e Inmunología Clínica

Reciba la revista gratis en su correo

Suscribase gratis a nuestra revista y recibala en su correo antes de su publicacion impresa.

Asociaciones que publican con nosotros:

Meducatium repositorio de informacion cientifica
Piedras 1333 2° C (C1240ABC) Ciudad Autónoma de Buenos Aires | Argentina | Argentina | tel./fax +54 11 5217-0292 | e-mail info@meducatium.com.ar | www.meducatium.com.ar

© Publicaciones Latinoamericanas S.R.L.

La plataforma Meducatium es un proyecto editorial de Publicaciones Latinoamericanas S.R.L.
Piedras 1333 2° C (C1240ABC) Ciudad Autónoma de Buenos Aires | Argentina | tel./fax (5411) 4362-1600 | e-mail info@publat.com.ar | www.publat.com.ar

Meducatium versión repositorio beta